




RealRate

PHARMACEUTICAL 2023

Landos Biopharma Inc
Rank 200 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Landos Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Landos Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Landos Biopharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 42% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	45,253
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,122
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	1,453
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	25,680
Selling, General and Administrative Expense	14,881

Output Variable	Value in 1000 USD
Assets	45,253
Liabilities	6,122
Expenses	40,561
Revenues	0
Stockholders Equity	39,131
Net Income	-40,561
Comprehensive Net Income	-39,834
BaseVar	46,694
ECR before Limited Liability	177%
Economic Capital Ratio	287%